Amsterdam-based NLC Health Ventures on Monday announced the launch of Exolvo Biosciences, a biotechnology company offering biological drug delivery solutions, in collaboration with Verily (an Alphabet Inc. company formerly known as Google LifeSciences).
Through Exolvo, NLC seeks to advance drug delivery technologies that were incubated within Verily and are now spun out as independent private early-stage ventures under NLC’s umbrella.
Exolvo’s oral drug delivery technology features flexible capsule sizes and a modular design that can accommodate a variety of large molecular structures.
“This technology has the potential to have a huge impact – for patients it will mean an improved and enhanced treatment experience, and for healthcare professionals it will mean simplified management and more efficient care delivery,” said Nick Ivereigh, UK lead partner at NLC.
The Need for Exolvo Biosciences
Biologics are essential for treating chronic diseases, but their size and complexity make oral administration challenging.
As a result, biologics are typically administered via frequent and painful needle injections or intravenous administration.
Such treatments can be burdensome for patients and costly for the health care system.
“When you talk to anyone living with a chronic disease like diabetes, they will tell you the struggles of having to inject themselves – in some cases multiple times a day. We need innovative solutions that can make treatment more accessible and less invasive for people living with chronic disease,” said Brian Longstreet, co-founder and CEO of Exolvo.
Exolvo Biosciences is a biotechnology company aiming to transform the oral delivery of large, complex molecules.
Using Verily’s technology, Exolvo aims to transform biological drug delivery, making therapies more accessible and less invasive.
Exolvo’s technology is progressing towards IND (Investigational New Drug) packaging in the United States while actively working with leading pharmaceutical and biotechnology company partners.
NLC Health Ventures: Active medical technology investor
Amsterdam-based NLC Health Ventures is Europe’s most active medtech investor and the largest medtech venture builder in the world.
NLC discovers, builds and scales transformative health innovations to deliver quality care to more patients.
NLC is a “BCorp” and its funds adhere to SFDR9 guidelines and contribute to ESG 3, 9 and 17.
With over 100 startups, 4 funds and operations in 16 countries, we are bringing impactful innovation to patients at scale.
The NLC Health Impact Fund is NLC’s newest and largest fund to invest in startup companies. The fund will inject capital into ventures at various stages, providing both seed and follow-on funding.
